Eli Lilly Launches Master Protocol for New Weight Loss Drugs

Obesity and overweight are significant global health challenges, affecting hundreds of millions worldwide and increasing the risk of numerous chronic diseases such as type 2 diabetes, cardiovascular disease, and certain cancers. While existing treatments like Tirzepatide have shown remarkable efficacy, there's a continuous need for diverse, potentially more effective, or better-tolerated interventions to address the varied needs of patients. This Phase 2 master protocol study aims to efficiently evaluate multiple novel drug candidates for chronic weight management, directly addressing the ongoing need for new, safe, and highly effective therapeutic options with diverse mechanisms of action.